Pamidronate Disodium | CAS#57248-88-1

MedKoo Cat#: 100700 | Name: Pamidronate Disodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pamidronate disodium is the disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Chemical Structure

Pamidronate Disodium

CAS#57248-88-1 (disodium heptahydrate)

Theoretical Analysis

MedKoo Cat#: 100700

Name: Pamidronate Disodium

CAS#: 57248-88-1 (disodium heptahydrate)

Chemical Formula: C3H23NNa2O14P2

Exact Mass: 0.0000

Molecular Weight: 405.13

Elemental Analysis: C, 8.89; H, 5.72; N, 3.46; Na, 11.35; O, 55.29; P, 15.29

Price and Availability

Size	Price	Availability
100mg	USD 90.00	Ready to ship
250mg	USD 150.00	Ready to ship
500mg	USD 190.00	Ready to ship
1g	USD 250.00	Ready to ship
2g	USD 450.00	Ready to ship
5g	USD 750.00	Ready to ship
10g	USD 1,250.00	Ready to ship
20g	USD 1,950.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

57248-88-1 (disodium heptahydrate) 40391-99-9 (free acid) 89131-02-2 (monosodium)

Synonym

US brand name: Aredia. Foreign brand name: Aminomux. Abbreviation: APD. Code name: GCP23339A.

IUPAC/Chemical Name

sodium (3-amino-1-hydroxypropane-1,1-diyl)bis(hydrogenphosphonate) heptahydrate

InChi Key

WUKFVUXKIJZXHK-UHFFFAOYSA-L

InChi Code

InChI=1S/C3H11NO7P2.2Na.7H2O/c4-2-1-3(5,10-12(6)7)11-13(8)9;;;;;;;;;/h5,12-13H,1-2,4H2,(H,6,7)(H,8,9);;;7*1H2/q;2*+1;;;;;;;/p-2

SMILES Code

OC(OP([O-])=O)(OP([O-])=O)CCN.[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[H]O[H].[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

DRUG DESCRIPTION Aredia, pamidronate disodium (APD), is a bone-resorption inhibitor available in 30-mg or 90-mg vials for intravenous administration. Each 30-mg and 90-mg vial contains, respectively, 30 mg and 90 mg of sterile, lyophilized pamidronate disodium and 470 mg and 375 mg of mannitol, USP. The pH of a 1% solution of pamidronate disodium in distilled water is approximately 8.3. Aredia, a member of the group of chemical compounds known as bisphosphonates, is an analog of pyrophosphate. Pamidronate disodium is designated chemically as phosphonic acid (3-amino-1-hydroxypropylidene) bis-, disodium salt, pentahydrate, (APD). Pamidronate disodium is a white-to-practically-white powder. It is soluble in water and in 2N sodium hydroxide, sparingly soluble in 0.1N hydrochloric acid and in 0.1N acetic acid, and practically insoluble in organic solvents. Its molecular formula is C3H9NO7P2Na2Â•5H2O and its molecular weight is 369.1. Inactive Ingredients. Mannitol, USP, and phosphoric acid (for adjustment to pH 6.5 prior to lyophilization). CLINICAL PHARMACOLOGY The principal pharmacologic action of Aredia is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment of hypercalcemia, Aredia inhibits bone resorption apparently without inhibiting bone formation and mineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that Aredia inhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by various tumors in animal studies.

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#YYP30917

QC Data

View QC data: current batch, Lot#YYP30917

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Pamidronate disodium is a bisphosphonate drug that can help to strengthen bones.

In vitro activity:

Pamidronate disodium 1, 5, and 10 μg/ml were unfavorable for bone marrow mesenchymal stem cell (BMMSC) growth (P < .05), whereas 0.1 and 0.5 μg/mL did not affect BMMSC growth (P ≥ .05). BMMSCs treated with pamidronate disodium 0.5 μg/mL had lower alkaline phosphatase (ALP) activity, ALP staining, and alizarin red S (ARS) staining (P < .05), and BMMSCs treated with low concentrations (<0.5 μg/mL) of pamidronate disodium had the same levels of ALP activity, ALP staining, and ARS staining as the control (0 μg/mL). Pamidronate disodium 0.5 μg/mL decreased the expression of genes and proteins involved in Wnt and β-catenin signaling. BMMSCs with Wnt3a and pamidronate disodium 0.5 μg/mL had higher ALP activity, ALP staining, and ARS staining (P < .05). Overall, pamidronate disodium inhibited Wnt and β-catenin signaling, which controls osteogenic differentiation in BMMSCs. Reference: J Oral Maxillofac Surg. 2017 Oct;75(10):2135-2143. https://www.joms.org/article/S0278-2391(17)30334-8/fulltext

In vivo activity:

Pamidronate was administered subcutaneously to nude mice either simultaneously or as post intracardiac injection of the human breast cancer MDA-MB-231 cells. Radiographs were used first to assess the presence of osteolytic bone metastases. Kaplan-Meier analysis demonstrated that animals treated with pamidronate early, but not late, showed a slower progression of bone metastases and hind limb paralysis than did vehicle-treated animals. Mann-Whitney analysis showed that only 44.4% of mice treated with pamidronate at the time of tumor cell inoculation developed bone metastases as compared to over 80% (p<0.05) of mice receiving vehicle alone. In contrast to X-ray analysis, morphometric analysis indicates that the number of lesions within bone was similar in pamidronate and vehicle-treated mice but that the lesions were significantly smaller and therefore, often not visible on radiographs. These results demonstrate that pamidronate is effective in reducing tumor burden in breast cancer metastatic to bone and is most effective as a preventative agent when administered closest in time to implantation of tumor cells. The data also suggest that pamidronate acts mainly by inhibiting the growth of established bone metastatic lesions but has no effect on the metastatic spread itself. Reference: Int J Oncol. 2003 Apr;22(4):883-90. https://www.spandidos-publications.com/ijo/22/4/883

	Solvent	mg/mL	mM
Solubility
	H2O	25.0	61.70

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 405.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Xu Y, Sun J, Yang X, Yu Y, Mai H, Li Z. Pamidronate Disodium Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells In Vitro. J Oral Maxillofac Surg. 2017 Oct;75(10):2135-2143. doi: 10.1016/j.joms.2017.03.016. Epub 2017 Mar 22. PMID: 28412267. 2. Marolt D, Cozin M, Vunjak-Novakovic G, Cremers S, Landesberg R. Effects of pamidronate on human alveolar osteoblasts in vitro. J Oral Maxillofac Surg. 2012 May;70(5):1081-92. doi: 10.1016/j.joms.2011.05.002. PMID: 21856057; PMCID: PMC3223542. 3. El-Abdaimi K, Ste-Marie LG, Papavasiliou V, Dion N, Cardinal PE, Huang D, Kremer R. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone. Int J Oncol. 2003 Apr;22(4):883-90. PMID: 12632083. 4. Evans KD, Sheppard LE, Rao SH, Martin RB, Oberbauer AM. Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta. Int J Biomed Sci. 2009 Dec;5(4):345-52. PMID: 23675157; PMCID: PMC3614807.

In vitro protocol:

In vivo protocol:

1. El-Abdaimi K, Ste-Marie LG, Papavasiliou V, Dion N, Cardinal PE, Huang D, Kremer R. Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone. Int J Oncol. 2003 Apr;22(4):883-90. PMID: 12632083. 2. Evans KD, Sheppard LE, Rao SH, Martin RB, Oberbauer AM. Pamidronate alters the growth plate in the oim mouse model for osteogenesis imperfecta. Int J Biomed Sci. 2009 Dec;5(4):345-52. PMID: 23675157; PMCID: PMC3614807.

1: Zhou T, Zhou Z, Wang Y. Photothermal Antibacterial and Osteoinductive Polypyrrole@Cu Implants for Biological Tissue Replacement. Materials (Basel). 2024 Aug 5;17(15):3882. doi: 10.3390/ma17153882. PMID: 39124546; PMCID: PMC11313605. 2: McKenna T, McKenna DE, Fernandes V, Korda M, Bradley U. Bisphosphonate- Induced Orbital Cellulitis in a Patient With Suspected Parathyroid Carcinoma: A Case Report. Cureus. 2024 Jul 1;16(7):e63577. doi: 10.7759/cureus.63577. PMID: 39087171; PMCID: PMC11290043. 3: Nagoshi R, Amari S, Abiko Y, Sano Wada Y, Ishiguro A, Horikawa R, Ito Y. Fatality owing to pulmonary hemorrhage following pamidronate disodium administration in a neonate with osteogenesis imperfecta type 2: A case report. Clin Pediatr Endocrinol. 2024;33(2):76-81. doi: 10.1297/cpe.2023-0061. Epub 2024 Feb 9. PMID: 38572388; PMCID: PMC10985016. 4: Sun T, Chen C, Liu K, Li L, Zhang R, Wen W, Ding S, Liu M, Zhou C, Luo B. A Wood-Derived Periosteum for Spatiotemporal Drug Release: Boosting Bone Repair through Anisotropic Structure and Multiple Functions. Adv Healthc Mater. 2024 Jul;13(19):e2400707. doi: 10.1002/adhm.202400707. Epub 2024 Apr 2. PMID: 38563114. 5: Yang S, Chen Z, Zhuang P, Tang Y, Chen Z, Wang F, Cai Z, Wei J, Cui W. Seamlessly Adhesive Bionic Periosteum Patches Via Filling Microcracks for Defective Bone Healing. Small Methods. 2023 Oct;7(10):e2300370. doi: 10.1002/smtd.202300370. Epub 2023 Jun 25. PMID: 37356079. 6: Dawson KA, Blong A, Walton R. Case report: Focal segmental glomerulosclerosis and nephrotic syndrome following treatment with pamidronate for calcitriol toxicity. Front Vet Sci. 2022 Aug 12;9:956153. doi: 10.3389/fvets.2022.956153. PMID: 36032307; PMCID: PMC9412160. 7: Bai Z, Wang J, Kang M, Guo P, Wang D. Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. Dis Markers. 2022 Aug 16;2022:5069918. doi: 10.1155/2022/5069918. PMID: 36016848; PMCID: PMC9398865. 8: Wang Y, Tang Z, Meng R, He L. Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis. Ann Palliat Med. 2021 Nov;10(11):11950-11959. doi: 10.21037/apm-21-3056. PMID: 34872319. 9: You H, Dang G, Lu B, Zhang S, Li C, Wang L, Hu Y, Chen H, Zhang J, He W. Serum Sp17 Autoantibody Serves as a Potential Specific Biomarker in Patients with SAPHO Syndrome. J Clin Immunol. 2021 Apr;41(3):565-575. doi: 10.1007/s10875-020-00937-w. Epub 2021 Jan 3. PMID: 33392854; PMCID: PMC7921076. 10: Veginadu P, Tavva SR, Muddada V, Gorantla S. Effect of pharmacological agents on relapse following orthodontic tooth movement. Angle Orthod. 2020 Jul 1;90(4):598-606. doi: 10.2319/092619-613.1. PMID: 33378496; PMCID: PMC8028453. 11: Kilinc S, Bostan O, Erol M, Erturk S, Dilek D, Yigit O. Successful management with bisphosphonate treatment in a child with tuberculosis-associated hypercalcemia. North Clin Istanb. 2020 May 27;7(4):411-414. doi: 10.14744/nci.2019.14890. PMID: 33043270; PMCID: PMC7521098. 12: Ono Y, Miyakoshi N, Hongo M, Kasukawa Y, Misawa A, Ishikawa Y, Kudo D, Shimada Y. Growing Rod Surgery for Early-Onset Scoliosis in an Osteogenesis Imperfecta Patient. World Neurosurg. 2020 Dec;144:178-183. doi: 10.1016/j.wneu.2020.08.165. Epub 2020 Sep 2. PMID: 32889193. 13: Li X, Jia K, An J, Zhang Y. Application of pamidronate disodium for the treatment of diffuse sclerosing osteomyelitis of the mandible: A clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Dec;130(6):616-624. doi: 10.1016/j.oooo.2020.06.023. Epub 2020 Jul 8. PMID: 32771415. 14: Liu J, Zhao C, Liu B, Liu H, Wang L. Analgesia and curative effect of pamidronate disodium combined with chemotherapy on elderly patients with advanced metastatic bone cancer. Oncol Lett. 2019 Jul;18(1):771-775. doi: 10.3892/ol.2019.10340. Epub 2019 May 10. PMID: 31289553; PMCID: PMC6540329. 15: Li C, Zhao Y, Zuo Y, Zhou Y, Zhang F, Liu S, Zhu Q, Chen J, Zhang W, Xu W, Gu Z, Li L, Li F, Tao W, Cao Y, Sun X, Jing H, Chen H, Zhang S, Dong Z, Liu J, Shi X, Hao W, Qiu G, Zhang W, Wu N, Wu Z. Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):663-669. Epub 2019 Feb 7. PMID: 30767869. 16: Li P, Hu Y. "Turn-Off" Fluorescent Sensor for Pamidronate Disodium and Zoledronic Acid Based on Newly Synthesized Carbon Dots from Black Tea. J Anal Methods Chem. 2018 Mar 13;2018:3631249. doi: 10.1155/2018/3631249. PMID: 29725552; PMCID: PMC5872615. 17: Vinod SS, Reed AB, Maxwell J, Cron RQ, Stoll ML. Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year. Pediatr Rheumatol Online J. 2018 Mar 9;16(1):16. doi: 10.1186/s12969-018-0234-0. PMID: 29523211; PMCID: PMC5845357. 18: Ronsoni MF, Santos HCD, Colombo BDS, Correa CG, Moritz APG, Coral MHC, Sande-Lee SV, Hohl A. Hypercalcemia and acute renal insufficiency following use of a veterinary supplement. J Bras Nefrol. 2017 Oct-Dec;39(4):467-469. English, Portuguese. doi: 10.5935/0101-2800.20170082. PMID: 29319776. 19: Tuncer I, Delilbasi C, Deniz E, Soluk Tekkesin M, Olgac V, Sencift K. Effects of pamidronate administration on tooth eruption and mandibular growth in new born rats. J Istanb Univ Fac Dent. 2017 Jan 2;51(1):8-14. doi: 10.17096/jiufd.16663. PMID: 28955580; PMCID: PMC5573489. 20: Ong MWS, Jones L. Improving Bisphosphonate Infusion Monitoring at Haematology Medical Day Unit. BMJ Qual Improv Rep. 2017 Mar 31;6(1):u206586.w4692. doi: 10.1136/bmjquality.u206586.w4692. PMID: 28469896; PMCID: PMC5388016.